English
Regional settings| Spread | 0.10 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 16.26 |
| Open | 16.31 |
| 1-Year Change | -31.87% |
| Day's Range | 16.31 - 16.69 |
Certara, Inc. is a provider of biosimulation software and technology-enabled services. The Company is focused on producing medicines for patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. The Company builds its biosimulation technology on the first principles of biology, chemistry, and pharmacology with mathematical algorithms that model how medicines and diseases behave in the body. Its software and technology-enabled services include Mechanistic Biosimulation Platform (Simcyp); Empirical Pharmacokinetic and Pharmacodynamic Biosimulation (Phoenix); Scientific Informatics Platform (D360); Clinical Outcomes Databases for Biosimulation (CODEx); Authoring and Management of Regulatory Submissions Platform (GlobalSubmit), And Market Access Communication Platform (BaseCase).
BRIEF: For the fiscal year ended 31 December 2021, Certara Inc revenues increased 17% to $286.1M. Net loss decreased 73% to $13.3M. Revenues reflect United States segment increase of 13% to $205.4M, EMEA segment increase of 32% to $56.4M. Lower net loss reflects Stock-based Compensation in SGA decrease of 53% to $19.2M (expense), Stock-based Compensation in SGA decrease of 70% to $2.2M (expense).
